KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$69.9 million.

  • Arbutus Biopharma's Net Income towards Common Stockholders rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Net Income towards Common Stockholders of -$69.9 million as of FY2024, which was up 4.02% from -$72.8 million recorded in FY2023.
  • In the past 5 years, Arbutus Biopharma's Net Income towards Common Stockholders registered a high of -$69.5 million during FY2022, and its lowest value of -$88.4 million during FY2021.
  • For the 3-year period, Arbutus Biopharma's Net Income towards Common Stockholders averaged around -$70.7 million, with its median value being -$69.9 million (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 53.98% in 2020, then dropped by 16.50% in 2021.
  • Yearly analysis of 5 years shows Arbutus Biopharma's Net Income towards Common Stockholders stood at -$75.9 million in 2020, then declined by 16.50% to -$88.4 million in 2021, then increased by 21.42% to -$69.5 million in 2022, then declined by 4.89% to -$72.8 million in 2023, then climbed by 4.02% to -$69.9 million in 2024.